SC
TARS icon

Stempoint Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Stempoint Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$41.3K – 71
2024
Q1 		$41.3K Buy
+50,000
New +$1.47M 0.01% 60

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Stempoint Capital's TARS Position: Q2 2024 in Review

Stempoint Capital sold out of Tarsus Pharmaceuticals (TARS) in Q2 2024, closing a stake of 222,253 shares — an estimated $8.08M sold.

Stempoint Capital first reported a position in TARS in Q4 2023 and held it in 2 quarters. The position peaked at $8.08M in Q1 2024. 148 funds tracked by Wall St. Rank hold TARS as of Q2 2024.

  • Stempoint Capital reported no remaining Tarsus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Stempoint Capital sold 222,253 Tarsus Pharmaceuticals shares in Q2 2024, an estimated $8.08M.
  • Stempoint Capital first reported a position in Tarsus Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Stempoint Capital's Tarsus Pharmaceuticals position peaked at $8.08M in Q1 2024.
  • 148 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2024.

Based on Stempoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.